Literature DB >> 25538218

A 'silent', new polymorphism of factor H and apparent de novo atypical haemolytic uraemic syndrome after kidney transplantation.

Emine N Broeders1, Patrick Stordeur2, Sandrine Rorive3, Karin Dahan4.   

Abstract

The pathophysiology of atypical haemolytic-uraemic syndrome (aHUS) occurring de novo after renal transplantation may include genetic mutations of regulators of complement activation, but they are still rarely determined. A 41-year-old female renal transplant recipient presented two very different episodes of thrombotic microangiopathy. The first episode was associated with antibody-mediated rejection and the second was an isolated, acute aHUS, successfully treated with eculizumab. The diagnosis included a genetic analysis and we found a synonymous variant in the Complement Factor H (CFH) gene, c2634C>T (p.His878=) and low factor H (FH) activity during both events. In conclusion, the diagnosis of aHUS should be considered when TMA is associated with an AMR episode. In this setting, a silent polymorphism of factor H may be responsible for these rare cases of "de novo" aHUS after transplantation. 2014 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25538218      PMCID: PMC4275717          DOI: 10.1136/bcr-2014-207630

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  20 in total

1.  Eculizumab for atypical hemolytic-uremic syndrome.

Authors:  Jens Nürnberger; Thomas Philipp; Oliver Witzke; Anabelle Opazo Saez; Udo Vester; Hideo Andreas Baba; Andreas Kribben; Lothar Bernd Zimmerhackl; Andreas R Janecke; Mato Nagel; Michael Kirschfink
Journal:  N Engl J Med       Date:  2009-01-29       Impact factor: 91.245

2.  Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome.

Authors:  V Chatelet; V Frémeaux-Bacchi; T Lobbedez; M Ficheux; B Hurault de Ligny
Journal:  Am J Transplant       Date:  2009-09-22       Impact factor: 8.086

Review 3.  Atypical hemolytic-uremic syndrome.

Authors:  Marina Noris; Giuseppe Remuzzi
Journal:  N Engl J Med       Date:  2009-10-22       Impact factor: 91.245

Review 4.  Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies.

Authors:  Julien Zuber; Fadi Fakhouri; Lubka T Roumenina; Chantal Loirat; Véronique Frémeaux-Bacchi
Journal:  Nat Rev Nephrol       Date:  2012-10-02       Impact factor: 28.314

Review 5.  Silent SNPs: impact on gene function and phenotype.

Authors:  Anton A Komar
Journal:  Pharmacogenomics       Date:  2007-08       Impact factor: 2.533

6.  Determinants of poor graft outcome in patients with antibody-mediated acute rejection.

Authors:  C Lefaucheur; D Nochy; G S Hill; C Suberbielle-Boissel; C Antoine; D Charron; D Glotz
Journal:  Am J Transplant       Date:  2007-04       Impact factor: 8.086

7.  Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.

Authors:  C M Legendre; C Licht; P Muus; L A Greenbaum; S Babu; C Bedrosian; C Bingham; D J Cohen; Y Delmas; K Douglas; F Eitner; T Feldkamp; D Fouque; R R Furman; O Gaber; M Herthelius; M Hourmant; D Karpman; Y Lebranchu; C Mariat; J Menne; B Moulin; J Nürnberger; M Ogawa; G Remuzzi; T Richard; R Sberro-Soussan; B Severino; N S Sheerin; A Trivelli; L B Zimmerhackl; T Goodship; C Loirat
Journal:  N Engl J Med       Date:  2013-06-06       Impact factor: 91.245

8.  Thrombotic microangiopathy after renal transplantation in the United States.

Authors:  Joel C Reynolds; Lawrence Y Agodoa; Christina M Yuan; Kevin C Abbott
Journal:  Am J Kidney Dis       Date:  2003-11       Impact factor: 8.860

9.  Synonymous codon usage influences the local protein structure observed.

Authors:  Rhodri Saunders; Charlotte M Deane
Journal:  Nucleic Acids Res       Date:  2010-06-08       Impact factor: 16.971

10.  Generic algorithm to predict the speed of translational elongation: implications for protein biogenesis.

Authors:  Gong Zhang; Zoya Ignatova
Journal:  PLoS One       Date:  2009-04-03       Impact factor: 3.240

View more
  3 in total

Review 1.  Complement in Kidney Transplantation.

Authors:  Marek Cernoch; Ondrej Viklicky
Journal:  Front Med (Lausanne)       Date:  2017-05-30

Review 2.  Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use.

Authors:  Kioa L Wijnsma; Caroline Duineveld; Jack F M Wetzels; Nicole C A J van de Kar
Journal:  Pediatr Nephrol       Date:  2018-11-06       Impact factor: 3.714

3.  Poor allograft outcome in Indian patients with post-transplant C3 glomerulopathy.

Authors:  Ashwani Kumar; Raja Ramachandran; Amit Rawat; Reena Das; Charan S Rayat; Deepesh B Kenwar; Ashish Sharma; Krishan L Gupta; Ritambhra Nada
Journal:  Clin Kidney J       Date:  2019-11-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.